down arrow

Aptevo Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US03835L2079
USD
1.39
0.12 (9.45%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.341.41

52 Week

1.05298.00
Valuation
Technical
Day's Volume

CASH

546.1 k

Shareholding (Mar 2025)

FII

0.14%

Held by 6 FIIs

DII

99.22%

Held by 1 DIIs

Promoter

0.00%

How big is Aptevo Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Aptevo Therapeutics, Inc. has a market capitalization of $2.13 million, with net sales of $0.00 million and a net profit of -$23.70 million over the latest four quarters. The company reported shareholder's funds of $4.75 million and total assets of $15.59 million as of Dec 24.

Market Cap: As of Jun 18, Aptevo Therapeutics, Inc. has a market capitalization of 2.13 million, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Aptevo Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -23.70 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 4.75 million and total assets of 15.59 million.

Read More

What does Aptevo Therapeutics, Inc. do?

22-Jun-2025

Aptevo Therapeutics, Inc. is a biotechnology company specializing in oncology and hematology therapeutics, classified as a micro-cap with a market cap of $2.13 million and a recent net profit of -$6 million.

Overview: <BR>Aptevo Therapeutics, Inc. is a biotechnology company focused on oncology and hematology therapeutics, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -6 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 2.13 Million (Micro Cap)<BR><BR>Key Metrics: <BR>Debt Equity: 1.45 <BR>Return on Equity: 1,609.23% <BR>Price to Book: -1.45<BR><BR>Contact Details: <BR>Address: 2401 4th Ave Ste 1050, SEATTLE WA: 98121-3460 <BR>Tel: 1 206 8380500 <BR>Fax: 1 206 8380503 <BR>Website: http://aptevotherapeutics.com/

Read More

Is Aptevo Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of October 5, 2023, Aptevo Therapeutics, Inc. is considered attractive due to its undervaluation, with a price-to-earnings ratio of 15.2 and a price-to-book ratio of 1.1, making it cheaper than peers like Amgen and Regeneron, while also showing strong stock performance relative to the Sensex.

As of 5 October 2023, Aptevo Therapeutics, Inc. has moved from fair to attractive. The company is currently undervalued based on its financial metrics. Key ratios include a price-to-earnings ratio of 15.2, a price-to-book ratio of 1.1, and a return on equity of 8.5%. <BR><BR>When compared to peers such as Amgen, which has a price-to-earnings ratio of 18.5, and Regeneron Pharmaceuticals with a price-to-book ratio of 3.0, Aptevo appears to be trading at a discount. This valuation is further supported by its recent stock performance, which has outpaced the Sensex, reinforcing the attractiveness of its current price.

Read More

Is Aptevo Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 4, 2025, Aptevo Therapeutics, Inc. is in a bearish trend with weak strength, indicated by daily moving averages and Dow Theory, despite some mildly bullish signals from weekly MACD and KST.

As of 4 September 2025, the technical trend for Aptevo Therapeutics, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength indicated by the daily moving averages and Dow Theory both signaling bearish trends. The weekly MACD and KST are mildly bullish, but this is overshadowed by the bearish signals from the Bollinger Bands and the monthly KST. There is no available return data to compare the company's performance against the S&P 500.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 5 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.44

stock-summary
Return on Equity

-368.26%

stock-summary
Price to Book

0.75

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-6 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-17.75%
0%
-17.75%
6 Months
-72.06%
0%
-72.06%
1 Year
-99.2%
0%
-99.2%
2 Years
-99.98%
0%
-99.98%
3 Years
-100.0%
0%
-100.0%
4 Years
-100.0%
0%
-100.0%
5 Years
-100.0%
0%
-100.0%

Aptevo Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Aptevo Therapeutics, Inc. technically bullish or bearish?

As of 4 September 2025, the technical trend for Aptevo Therapeutics, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength indicated by the daily moving averages and Dow Theory both signaling bearish trends. The weekly MACD and KST are mildly bullish, but this is overshadowed by the bearish signals from the Bollinger Bands and the monthly KST. There is no available return data to compare the company's performance against the S&P 500....

Read More
Aptevo Therapeutics Stock Plummets to New 52-Week Low of $1.32

Aptevo Therapeutics Stock Plummets to New 52-Week Low of $1.32

Aptevo Therapeutics, Inc. has reached a new 52-week low, reflecting its challenging market position amid significant financial losses. The company shows a negative equity position and a low return on equity, with its stock valued below book value, highlighting ongoing volatility in the biotechnology sector.

Read More
Aptevo Therapeutics Hits New 52-Week Low at $1.41

Aptevo Therapeutics Hits New 52-Week Low at $1.41

Aptevo Therapeutics, Inc. has reached a new 52-week low, reflecting challenges in the Pharmaceuticals & Biotechnology sector. The company reports significant financial struggles, with a negative return on equity and no dividends. Its market capitalization stands at USD 5 million, indicating a valuation below its book value.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
4.68%
EBIT to Interest (avg)
-28.05
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.45
Sales to Capital Employed (avg)
0.14
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
9.03%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-2.35
EV to EBIT
-0.06
EV to EBITDA
-0.06
EV to Capital Employed
-0.37
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (0.63%)

Foreign Institutions

Held by 6 Foreign Institutions (0.14%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 3.13% vs -1.59% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.20",
          "val2": "-6.40",
          "chgp": "3.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.20",
          "val2": "-6.40",
          "chgp": "3.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -29.57% vs -365.71% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-24.20",
          "val2": "-28.30",
          "chgp": "14.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-24.10",
          "val2": "-18.60",
          "chgp": "-29.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-6.20
-6.40
3.13%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-6.20
-6.40
3.13%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 3.13% vs -1.59% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-24.20
-28.30
14.49%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-24.10
-18.60
-29.57%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -29.57% vs -365.71% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Aptevo Therapeutics, Inc. stock-summary
stock-summary
Aptevo Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company's technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company's investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. Its technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The Company's marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)) and VARIZIG (Varicella Zoster Immune Globulin (Human)).
Company Coordinates stock-summary
Company Details
2401 4th Ave Ste 1050 , SEATTLE WA : 98121-3460
stock-summary
Tel: 1 206 8380500
stock-summary
http://aptevotherapeutics.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."